Eravacycline: A New Treatment Option for Complicated Intra-Abdominal Infections in the Age of Multidrug Resistance

Abstract

Aim: Recently approved for use in complicated intra-abdominal infection, eravacycline is a novel fluorocycline with broad spectrum of activity against resistant Gram-negative pathogens. This manuscript is a pooled analysis of two Phase III trials. Clinical efficacy: Clinical cure rates were 86.8% for eravacycline versus 87.6% for ertapenem, and 90.8% for eravacycline versus 91.2% for meropenem in the Intent to Treat (micro-ITT) populations, and 87.0% for eravacycline versus 88.8% ertapenem, and 92.4 versus 91.6% for meropenem in the Modified Intent to Treat (MITT) populations. Safety: Eravacycline is well tolerated, with lower rates of nausea, vomiting and diarrhea than other tetracyclines. Conclusion: Eravacycline is an effective new option for use in complicated intra-abdominal infections, and in particular, for the treatment of extended-spectrum β-lactamase- and carbapenem-resistant Enterobacteriaceae-expressing organisms.

Keywords::

• antibiotics
• antimicrobial resistance
• complicated intra-abdominal infection
• CRE
• eravacycline
• ESBL
• Gram-negative
• tetracycline

Acknowledgments

The authors would like to acknowledge assistance with research from Ekaterina Efimova, Tetraphase Pharmaceuticals Inc.

Data sharing statement

The authors certify that this manuscript reports the secondary analysis of clinical trial data that have been shared with them, and that the use of this shared data is in accordance with the terms (if any) agreed upon their receipt. The source of this data is: NCT01844856, NCT02784704.

Financial & competing interests disclosure

K Lawrence, M Olesky, S Izmailyan and L Tsai are employees of Tetraphase Pharmaceuticals. JS Solomkin and A Sway received funds from Tetraphase Pharmaceuticals for the preparation of this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

K Lawrence, M Olesky, S Izmailyan and L Tsai are employees of Tetraphase Pharmaceuticals. JS Solomkin and A Sway received funds from Tetraphase Pharmaceuticals for the preparation of this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.